Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A prospective single-arm clinical trial

Tomoki Suichi, Sonoko Misawa, Kengo Nagashima, Yasunori Sato, Yuta Iwai, Kanako Katayama, Yukari Sekiguchi, Kazumoto Shibuya, Hiroshi Amino, Yo Ichi Suzuki, Atsuko Tsuneyama, Keigo Nakamura, Satoshi Kuwabara

研究成果: Article査読

抄録

Objective A randomized controlled trial has shown the efficacy of thalidomide against polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; however, there are still refractory patients. We studied the effects of lenalidomide, a derivative of thalidomide, on patients refractory to thalidomide. Methods This prospective single-arm trial evaluated the safety and efficacy of lenalidomide plus dexamethasone in refractory or recurrent patients with POEMS syndrome. The regimen was administered as six 28-day cycles with lenalidomide on days 1-21 (15 mg in cycle 1, and 25 mg in cycle 2-6) plus dexamethasone once a week (20 mg). The primary endpoints were the rate of reduction in the serum vascular endothelial growth factor (VEGF) level at 24 weeks and the incidence of adverse events. This trial was registered with ClinicalTrial.gov, NCT02193698. Results Between July 2014 and December 2015, five men were enrolled. All patients had been refractory to thalidomide plus dexamethasone for more than 24 weeks. The mean rate of reduction in the serum VEGF level at 24 weeks was 59.6%±8.3% (p=0.0003). The mean serum VEGF level decreased from 2,466±771 pg/ mL to 974±340 pg/mL. No serious adverse events were observed, and all patients completed six cycles treatment. Discussion Lenalidomide is a therapeutic option for thalidomide-refractory patients with POEMS syndrome.

本文言語English
ページ(範囲)1149-1153
ページ数5
ジャーナルInternal Medicine
59
9
DOI
出版ステータスPublished - 2020

ASJC Scopus subject areas

  • Internal Medicine

フィンガープリント 「Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A prospective single-arm clinical trial」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル